Financial Performance - For the year ended December 31, 2025, the revenue was RMB 3,417,355,000, an increase of approximately 15.2% compared to RMB 2,967,235,000 for the year ended December 31, 2024[4] - The profit attributable to equity shareholders for the year ended December 31, 2025, was RMB 1,078,067,000, representing an increase of approximately 18.4% from RMB 910,458,000 for the year ended December 31, 2024[4] - Basic and diluted earnings per share for the year ended December 31, 2025, were approximately RMB 1.27 and RMB 1.26, respectively, reflecting increases of about 14.4% and 15.6% from RMB 1.11 and RMB 1.09 for the year ended December 31, 2024[4] - The total comprehensive income for the year ended December 31, 2025, was RMB 1,089,750,000, compared to RMB 917,551,000 for the year ended December 31, 2024[6] - The operating profit for the year ended December 31, 2025, was RMB 1,202,379,000, compared to RMB 1,045,060,000 for the year ended December 31, 2024[5] - Pre-tax profit for 2025 was RMB 1,196,422,000, an increase from RMB 1,020,106,000 in 2024, representing a growth of approximately 17.3%[34] - The gross profit for 2025 was RMB 2,667,120,000, an increase of about 19.0% from RMB 2,242,102,000 in 2024, with a gross margin of approximately 78.0%, up 2.4 percentage points from 75.6%[79] Assets and Liabilities - The total assets less current liabilities as of December 31, 2025, amounted to RMB 4,979,706,000, an increase from RMB 4,482,282,000 as of December 31, 2024[8] - The net asset value as of December 31, 2025, was RMB 4,837,870,000, compared to RMB 4,393,052,000 as of December 31, 2024[8] - The total assets for reportable segments rose to RMB 6,296,016,000 in 2025, compared to RMB 5,851,628,000 in 2024, marking an increase of 7.6%[22] - The total bank loans amounted to RMB 200,000,000, a decrease from RMB 253,340,000 in 2024[63] - The total lease liabilities as of December 31, 2025, were RMB 12,920,000, compared to RMB 13,829,000 in 2024[64] Dividends - The company proposed a final dividend of HKD 0.40 per share for the year ended December 31, 2025[4] - The interim dividend per share for ordinary shares is HKD 0.33 for 2025, an increase from HKD 0.30 in 2024, totaling RMB 253,308,000, compared to RMB 229,827,000 in 2024[38] - The proposed final dividend per share for ordinary shares is HKD 0.40 for 2025, up from HKD 0.30 in 2024, amounting to RMB 296,201,000, compared to RMB 235,954,000 in 2024[38] Costs and Expenses - The financing costs for the year ended December 31, 2025, were RMB 4,360,000, significantly reduced from RMB 24,888,000 for the year ended December 31, 2024[5] - Employee costs rose to RMB 678,611,000 in 2025 from RMB 593,172,000 in 2024, reflecting an increase of about 14.4%[4] - Administrative expenses increased by approximately 42.9% to RMB 445,631,000 in 2025, up from RMB 311,873,000 in 2024, mainly due to organizational restructuring and increased R&D expenses[82] - Distribution costs rose by approximately 9.3% to RMB 1,072,775,000 in 2025, compared to RMB 981,576,000 in 2024, with the growth rate significantly lower than revenue growth[81] Research and Development - Research and development costs for 2025 amounted to RMB 151,844,000, up from RMB 97,541,000 in 2024, indicating a significant increase of approximately 55.6%[29] - The group made significant progress in R&D, with SK-08 and SK-09 receiving IND approval from the FDA, marking a breakthrough in global drug development[70] - The group launched a multi-modal AIDD platform to optimize drug design and reduce development costs, enhancing R&D efficiency[70] - The establishment of an international scientific advisory board aims to enhance the development of new drugs for chronic kidney disease, with Dr. Jonathan Barratt as the first advisor[71] Inventory and Receivables - The company reported a decrease in inventory to RMB 271,405,000 as of December 31, 2025, from RMB 289,677,000 as of December 31, 2024[7] - Trade receivables, net of impairment, increased to RMB 251,321,000 in 2025 from RMB 234,186,000 in 2024[56] - As of December 31, 2025, inventory balance was RMB 271,405,000, a decrease of approximately 6.3% compared to RMB 289,677,000 on December 31, 2024, with inventory turnover days reduced by 28.8 days to 136.5 days[87] Corporate Governance and Compliance - The company has maintained compliance with relevant laws and regulations without any significant violations for the year ending December 31, 2025[109] - The audit committee, composed of three independent non-executive directors, has reviewed the financial controls and risk management systems to ensure effective oversight[115] - The company has adopted corporate governance principles and standards, aiming for continuous improvement in compliance efficiency and effectiveness[111] - The roles of the chairman and CEO have been clearly delineated to enhance independence and ensure a balance of power and authority[112] Market and Industry Trends - The company experienced a significant shift in the pharmaceutical industry towards value creation rather than scale expansion due to regulatory changes[66] - The overall growth rate of the industry is slowing, but structural opportunities remain for innovative and irreplaceable products and services[66] - The company has been closely monitoring recent developments in national policies affecting the pharmaceutical industry, which are considered major uncertainties[107] Cash Flow and Financing - Net cash generated from operating activities for 2025 was RMB 1,211,796,000, an increase of approximately 11.5% from RMB 1,086,987,000 in 2024[90] - Cash and bank balances, including financial products, increased by approximately 13.4% to RMB 4,383,691,000 as of December 31, 2025[91] - The capital debt ratio decreased by 1.8 percentage points to 4.4% as of December 31, 2025, due to a reduction in net bank loans and an increase in equity attributable to shareholders[94] Shareholder Information - The board proposed a final dividend of HKD 0.4 per share for the year ending December 31, 2025, subject to shareholder approval at the annual general meeting on May 26, 2026[121] - The final dividend, if approved, is expected to be paid on or around June 22, 2026, to shareholders listed on the register as of June 10, 2026[121] - Shareholders must submit completed share transfer documents by 4:30 PM on May 19, 2026, to be eligible to attend and vote at the annual general meeting[122]
康臣药业(01681) - 2025 - 年度业绩